

BACE1 Antibody

Rabbit Anti Human Polyclonal Antibody

Catalog # ABV11704

Product Information

Application	WB
Primary Accession	P56817
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	55764

Additional Information

Gene ID	23621
Positive Control	Western blot: Recombinant protein
Application & Usage	Western blot: ~1:200
Other Names	ASP2, BACE, HSPC104, KIAA1149, Beta-secretase-1, memapsin-2, aspartyl-protease-2, beta-site-APP-cleaving-enzyme-1
Target/Specificity	BACE1
Antibody Form	Liquid
Appearance	Colorless liquid
Formulation	30 μ g (0.5 mg/ml) of antibody in PBS pH 7.2 containing 0.01 % BSA, 0.01 % thimerosal, and 50 % glycerol.
Handling	The antibody solution should be gently mixed before use.
Reconstitution & Storage	-20 °C
Background Descriptions Precautions	BACE1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	BACE1 (HGNC:933)
Synonyms	BACE, KIAA1149
Function	Responsible for the proteolytic processing of the amyloid precursor protein

(APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase (PubMed:[10656250](#), PubMed:[10677483](#), PubMed:[20354142](#)). Cleaves CHL1 (By similarity).

Cellular Location

Cell membrane; Single-pass type I membrane protein Golgi apparatus, trans-Golgi network. Endoplasmic reticulum. Endosome. Cell surface. Cytoplasmic vesicle membrane; Single-pass type I membrane protein. Membrane raft {ECO:0000250|UniProtKB:P56818}. Lysosome. Late endosome. Early endosome. Recycling endosome. Cell projection, axon {ECO:0000250|UniProtKB:P56818}. Cell projection, dendrite {ECO:0000250|UniProtKB:P56818}. Note=Predominantly localized to the later Golgi/trans-Golgi network (TGN) and minimally detectable in the early Golgi compartments. A small portion is also found in the endoplasmic reticulum, endosomes and on the cell surface (PubMed:11466313, PubMed:17425515). Colocalization with APP in early endosomes is due to addition of bisecting N-acetylglucosamine which blocks targeting to late endosomes and lysosomes (By similarity) Retrogradly transported from endosomal compartments to the trans-Golgi network in a phosphorylation- and GGA1- dependent manner (PubMed:15886016). {ECO:0000250|UniProtKB:P56818, ECO:0000269|PubMed:11466313, ECO:0000269|PubMed:15886016, ECO:0000269|PubMed:17425515}

Tissue Location

Expressed at high levels in the brain and pancreas. In the brain, expression is highest in the substantia nigra, locus coeruleus and medulla oblongata.

Background

Beta-secretase 1 (BACE1) also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β -Secretase, and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid- β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.